TRACON Pharmaceuticals (NASDAQ:TCON) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.
This is a breakdown of current recommendations and price targets for TRACON Pharmaceuticals and Solid Biosciences, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Insider & Institutional Ownership
58.1% of TRACON Pharmaceuticals shares are held by institutional investors. Comparatively, 68.3% of Solid Biosciences shares are held by institutional investors. 23.3% of TRACON Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This table compares TRACON Pharmaceuticals and Solid Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
TRACON Pharmaceuticals has a beta of 3.1, suggesting that its share price is 210% more volatile than the S&P 500. Comparatively, Solid Biosciences has a beta of 1.83, suggesting that its share price is 83% more volatile than the S&P 500.
Valuation & Earnings
This table compares TRACON Pharmaceuticals and Solid Biosciences’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|TRACON Pharmaceuticals||$3.00 million||7.28||-$34.96 million||($1.30)||-0.56|
|Solid Biosciences||N/A||N/A||-$74.80 million||($2.25)||-3.91|
TRACON Pharmaceuticals has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than TRACON Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
TRACON Pharmaceuticals beats Solid Biosciences on 8 of the 12 factors compared between the two stocks.
TRACON Pharmaceuticals Company Profile
TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (AMD), and fibrotic diseases. Its lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trials for wet AMD. The company's other product candidates comprise TRC102, a small molecule that is in Phase II clinical trials for mesothelioma, Phase II clinical trials for glioblastoma, Phase I clinical trial for solid tumors, Phase I/II clinical trials for solid tumors and lymphomas, as well as Phase I clinical trial for lung cancer; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trials for the treatment prostate cancer. Its preclinical development product includes TRC694, an orally bioavailable inhibitor of NF-kB inducing kinase for the treatment of patients with hematologic malignancies, including myeloma. The company has a license agreement with Ambrx, Inc., and Santen Pharmaceutical Co., Ltd; a strategic partnership with I-Mab, as well as strategic licensing collaboration with Janssen Pharmaceutica N.V. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.
Solid Biosciences Company Profile
Solid Biosciences Inc. engages in identifying and developing therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, a gene therapy that is in Phase I/II clinical trials to restore functional dystrophin protein expression in patients' muscles. The company's product candidates also comprise SB-001, a monoclonal antibody to reduce fibrosis and inflammation. In addition, it is developing soft wearable assistive devices that have functional and therapeutic benefits to DMD patients. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.